Zydus Company Profile
✉ Email this page to a colleague
What is the competitive landscape for ZYDUS, and what generic alternatives to ZYDUS drugs are available?
ZYDUS has three hundred and seventy-eight approved drugs.
There is one US patent protecting ZYDUS drugs. There are twenty-six tentative approvals on ZYDUS drugs.
There are four patent family members on ZYDUS drugs in four countries and nine hundred and fifty-seven supplementary protection certificates in eighteen countries.
Summary for Zydus
| International Patents: | 4 |
| US Patents: | 1 |
| Tradenames: | 306 |
| Ingredients: | 296 |
| NDAs: | 378 |
| Patent Litigation for Zydus: | See patent lawsuits for Zydus |
Drugs and US Patents for Zydus
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Zydus Pharms | ATAZANAVIR SULFATE | atazanavir sulfate | CAPSULE;ORAL | 210575-003 | Jun 4, 2020 | DISCN | No | No | ⤷ Subscribe | ⤷ Subscribe | |||||
| Zydus Hlthcare | DULOXETINE HYDROCHLORIDE | duloxetine hydrochloride | CAPSULE, DELAYED REL PELLETS;ORAL | 090739-002 | Jan 8, 2014 | AB | RX | No | No | ⤷ Subscribe | ⤷ Subscribe | ||||
| Zydus Pharms Usa | RAMIPRIL | ramipril | CAPSULE;ORAL | 078832-002 | Sep 2, 2008 | AB | RX | No | No | ⤷ Subscribe | ⤷ Subscribe | ||||
| Zydus Lifesciences | ROPINIROLE HYDROCHLORIDE | ropinirole hydrochloride | TABLET;ORAL | 090411-005 | Jun 1, 2009 | AB | RX | No | No | ⤷ Subscribe | ⤷ Subscribe | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Paragraph IV (Patent) Challenges for ZYDUS drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Delayed-release Tablets | 20 mg | ➤ Subscribe | 2015-06-03 |
| ➤ Subscribe | for Injection | 200 mcg/vial | ➤ Subscribe | 2015-05-01 |
| ➤ Subscribe | for Injection | 100 mcg/vial and 500 mcg/vial | ➤ Subscribe | 2015-04-14 |
International Patents for Zydus Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 2015128877 | ⤷ Subscribe |
| South Africa | 201606075 | ⤷ Subscribe |
| Philippines | 12016501686 | ⤷ Subscribe |
| India | 651MU2014 | ⤷ Subscribe |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Zydus Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0193926 | C980031 | Netherlands | ⤷ Subscribe | PRODUCT NAME: RIVASTIGMINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER RIVASTIGMINE WATERSTOFTAR- TRAAT; REGISTRATION NO/DATE: EU/1/98/066/001 - EU/1/98/066/012 19980512 |
| 0247633 | 97C0118 | France | ⤷ Subscribe | PRODUCT NAME: ATORVASTATINE CALCIQUE TRIHYDRATE; REGISTRATION NO/DATE IN FRANCE: NL 21960 DU 19970321; REGISTRATION NO/DATE AT EEC: PL 00018/0240 DU 19961107 |
| 2487162 | 17C1002 | France | ⤷ Subscribe | PRODUCT NAME: COBICISTAT OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE OU UN SOLVATE ET LE DARUNAVIR OU SEL PHARMACEUTIQUEMENT ACCEPTABLE OU UN SOLVATE, EN PARTICULIER L'ETHANOLATE DE DARUNAVIR; REGISTRATION NO/DATE: EU/1/14/967 20141121 |
| 1915993 | 92315 | Luxembourg | ⤷ Subscribe | PRODUCT NAME: COMBINAISON COMPRENANT ALISKIREN,OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLE,ET AMLODIPINE,OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLE |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
